PHASE II TRIAL OF CONCURRENT BIOCHEMOTHERAPY (C-BC) WITH DECRESECENDO INTERLEUKIN-2 (D-IL-2), TAMOXIFEN (T), AND G-CSF UPPORT IN PATIENTS WITH METASTATIC MELANOMA (MM)

O DAY, S.J., BOASBERG, P., & GUA, M.. (1997). PHASE II TRIAL OF CONCURRENT BIOCHEMOTHERAPY (C-BC) WITH DECRESECENDO INTERLEUKIN-2 (D-IL-2), TAMOXIFEN (T), AND G-CSF UPPORT IN PATIENTS WITH METASTATIC MELANOMA (MM). PROCEEDING OF AMERICAN SOCIETY OF CLINICAL ONCOLOGY, 16(-), 490-490. SID. https://sid.ir/paper/534157/en

O DAY S.J., BOASBERG P., GUA M.. PHASE II TRIAL OF CONCURRENT BIOCHEMOTHERAPY (C-BC) WITH DECRESECENDO INTERLEUKIN-2 (D-IL-2), TAMOXIFEN (T), AND G-CSF UPPORT IN PATIENTS WITH METASTATIC MELANOMA (MM). PROCEEDING OF AMERICAN SOCIETY OF CLINICAL ONCOLOGY[Internet]. 1997;16(-):490-490. Available from: https://sid.ir/paper/534157/en

S.J. O DAY, P. BOASBERG, and M. GUA, “PHASE II TRIAL OF CONCURRENT BIOCHEMOTHERAPY (C-BC) WITH DECRESECENDO INTERLEUKIN-2 (D-IL-2), TAMOXIFEN (T), AND G-CSF UPPORT IN PATIENTS WITH METASTATIC MELANOMA (MM),” PROCEEDING OF AMERICAN SOCIETY OF CLINICAL ONCOLOGY, vol. 16, no. -, pp. 490–490, 1997, [Online]. Available: https://sid.ir/paper/534157/en